We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
Cap. Flow
-$719M
Cap. Flow %
-15.57%
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$97.5M
2
SGRY icon
Surgery Partners
SGRY
+$75.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$60M
4
PRTA icon
Prothena Corp
PRTA
+$57.7M
5
ARGX icon
argenx
ARGX
+$49.8M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$280M
2
BIIB icon
Biogen
BIIB
+$160M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$120M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$104M
5
HUM icon
Humana
HUM
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNAD
76
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$2.01M 0.04%
200,000
– –
SCYX icon
77
SCYNEXIS
SCYX
$37.2M
$1.78M 0.04%
142,575
– –
HYPR icon
78
Hyperfine
HYPR
$90.7M
$1.26M 0.03%
1,503,754
– –
FATE icon
79
Fate Therapeutics
FATE
$277M
$1.06M 0.02%
+104,653
New +$1.97M
ZLAB icon
80
Zai Lab
ZLAB
$2.07B
$961K 0.02%
31,309
-1,202,691
-97% -$37.9M
COLL icon
81
Collegium Pharmaceutical
COLL
$1.18B
$879K 0.02%
+37,898
New +$764K
ACIU icon
82
AC Immune
ACIU
$233M
$664K 0.01%
325,400
+50,524
+18% +$130K
REUN
83
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$504K 0.01%
560,300
-34,900
-6% -$50.9K
NUVB.WS
84
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$14.4K ﹤0.01%
99,999
– –
MSACW
85
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$5.2K ﹤0.01%
57,770
– –
ALNY icon
86
Alnylam Pharmaceuticals
ALNY
$38.1B
– –
-288,500
Closed -$57.7M
APLS
87
DELISTED
Apellis Pharmaceuticals
APLS
– –
-844,000
Closed -$57.6M
ATEC icon
88
Alphatec Holdings
ATEC
$1.46B
– –
-1,715,000
Closed -$15M
AVTR icon
89
Avantor
AVTR
$9.71B
– –
-4,522,600
Closed -$88.6M
BIIB icon
90
Biogen
BIIB
$30.8B
– –
-600,000
Closed -$160M
CNC icon
91
Centene
CNC
$30.5B
– –
-432,400
Closed -$33.6M
COGT icon
92
Cogent Biosciences
COGT
$6.82B
– –
-1,357,700
Closed -$20.3M
ELV icon
93
Elevance Health
ELV
$81.7B
– –
-207,600
Closed -$94.3M
ERAS icon
94
Erasca
ERAS
$6.18B
– –
-982,500
Closed -$7.66M
GOSS icon
95
Gossamer Bio
GOSS
$94.9M
– –
-1,450,000
Closed -$17.4M
HUM icon
96
Humana
HUM
$42.8B
– –
-212,000
Closed -$103M
IOVA icon
97
Iovance Biotherapeutics
IOVA
$2.07B
– –
-1,382,900
Closed -$13.2M
NKTX icon
98
Nkarta
NKTX
$152M
– –
-1,414,082
Closed -$18.6M
SIBN icon
99
SI-BONE Inc
SIBN
$815M
– –
-996,700
Closed -$17.4M
STOK icon
100
Stoke Therapeutics
STOK
$1.82B
– –
-891,100
Closed -$11.4M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2022 Portfolio in Review

As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management withdrew a net $719M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials.

Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.

  • Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
  • Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
  • Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
  • Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
  • Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
  • Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.